AIDS & TB Unit, Ministry of Health & Child Welfare, 2nd Floor, Mkwati Building, Corner Livingstone Avenue and Fifth Street, Harare, Zimbabwe.
BMC Public Health. 2012 Feb 13;12:124. doi: 10.1186/1471-2458-12-124.
Zimbabwe is a Southern African country with a high HIV-TB burden and is ranked 19th among the 22 Tuberculosis high burden countries worldwide. Recurrent TB is an important problem for TB control, yet there is limited information about treatment outcomes in relation to HIV status. This study was therefore conducted in Chitungwiza, a high density dormitory town outside the capital city, to determine in adults registered with recurrent TB how treatment outcomes were affected by type of recurrence and HIV status.
Data were abstracted from the Chitungwiza district TB register for all 225 adult TB patients who had previously been on anti-TB treatment and who were registered as recurrent TB from January to December 2009. The Chi-square and Fischer's exact tests were used to establish associations between categorical variables. Multivariate relative risks for associations between the various TB treatment outcomes and HIV status, type of recurrent TB, sex and age were calculated using Poisson regression with robust error variance.
Of 225 registered TB patients with recurrent TB, 159 (71%) were HIV tested, 135 (85%) were HIV-positive and 20 (15%) were known to be on antiretroviral treatment (ART). More females were HIV-tested (75/90, 83%) compared with males (84/135, 62%). There were 103 (46%) with relapse TB, 32 (14%) with treatment after default, and 90 (40%) with "retreatment other" TB. There was one failure patient. HIV-testing and HIV-positivity were similar between patients with different types of TB. Overall, treatment success was 73% with transfer-outs at 14% being the most common adverse outcome. TB treatment outcomes did not differ by HIV status. However those with relapse TB had better treatment success compared to "retreatment other" TB patients, (adjusted RR 0.81; 95% CI 0.68 - 0.97, p = 0.02).
No differences in treatment outcomes by HIV status were established in patients with recurrent TB. Important lessons from this study include increasing HIV testing uptake, a better understanding of what constitutes "retreatment other" TB, improved follow-up of true outcomes in patients who transfer-out and better recording practices related to HIV care and treatment especially for ART.
津巴布韦是南部非洲的一个国家,艾滋病毒/结核病负担沉重,在全球 22 个结核病高负担国家中排名第 19 位。复发性结核病是结核病控制的一个重要问题,但关于与艾滋病毒状况相关的治疗结果的信息有限。因此,这项研究在首都以外的高密度宿舍城镇奇通圭扎进行,目的是确定在登记的复发性结核病成人中,复发类型和艾滋病毒状况如何影响治疗结果。
从 2009 年 1 月至 12 月期间奇通圭扎区结核病登记处,为所有 225 名以前接受过抗结核治疗并登记为复发性结核病的成年结核病患者提取数据。卡方检验和费舍尔精确检验用于确定分类变量之间的关联。使用泊松回归和稳健误差方差计算与各种结核病治疗结果和艾滋病毒状况、复发性结核病类型、性别和年龄之间的关联的多变量相对风险。
在 225 名登记的复发性结核病患者中,有 159 名(71%)接受了艾滋病毒检测,135 名(85%)艾滋病毒检测呈阳性,20 名(15%)已知正在接受抗逆转录病毒治疗(ART)。接受艾滋病毒检测的女性比例(75/90,83%)高于男性(84/135,62%)。103 例(46%)为复发结核病,32 例(14%)为治疗后失访,90 例(40%)为“其他复治”结核病。有一名治疗失败患者。不同类型结核病患者的艾滋病毒检测和艾滋病毒阳性率相似。总的来说,治疗成功率为 73%,转出率为 14%,是最常见的不良结局。艾滋病毒状况对治疗结果无影响。然而,与“其他复治”结核病患者相比,复发结核病患者的治疗成功率更高,(调整后的 RR 0.81;95%CI 0.68-0.97,p=0.02)。
在复发性结核病患者中,未发现艾滋病毒状况对治疗结果有影响。从这项研究中得出的重要经验教训包括增加艾滋病毒检测率、更好地了解什么是“其他复治”结核病、改善对转出患者真实结局的随访、以及更好地记录与艾滋病毒护理和治疗相关的做法,特别是抗逆转录病毒治疗。